Bavarian Nordic meets recruitment target for RSV study
The late-stage trial, which is Danish drugmaker’s largest to date, will assesses the effect of a vaccine candidate against RSV infection in older adults.
by marketwire, translated by daniel pedersen
Bavarian Nordic has finished recruiting patients for the last part of its phase III study of a vaccine candidate against respiratory syncytial virus, RSV.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer predicts billion-dollar RSV sales
For subscribers
